文献速递呼吸危重症与机械通气

中重度ARDS辅助治疗使用模式:LUNG SAFE研究启示

Patterns of Use of Adjunctive Therapies in Patients With Early Moderate to Severe ARDS: Insights From the LUNG SAFE Study.
PubMed 文献 · Chest · 2020-02-20

LUNG SAFE研究是一项国际多中心前瞻性队列研究,纳入2014年50国459个ICU的机械通气中重度ARDS患者(P/F<150)。结果显示,1146例中71%在48小时内未接受任何辅助治疗,仅29%接受辅助治疗,其中75%为单一策略。非存活者中67%未接受辅助治疗。

要点

  • 中重度ARDS患者48小时内辅助治疗使用率仅29%,非存活者中67%未使用。
  • 接受辅助治疗者更年轻、病情更重、多因肺炎、更易被识别为ARDS。
  • 使用特殊辅助治疗者中67%未同时使用俯卧位或神经肌肉阻滞。

核心结论

  • 中重度ARDS患者48小时内辅助治疗使用率低,非存活者中多数未接受辅助治疗。

研究设计与样本

  • LUNG SAFE为国际多中心前瞻性队列研究,2014年在50国459个ICU开展。
  • 本亚组分析纳入1146例接受有创通气的早期中重度ARDS患者(P/F<150)。

主要发现

  • 1146例中811例(71%)在ARDS onset后48小时内未接受任何辅助治疗。
  • 335例(29%)接受辅助治疗,其中252例(75%)接受单一策略,83例(25%)接受多于一种。
  • ARDS非存活者中67%在48小时内未接受任何辅助治疗。
  • 接受特殊辅助治疗的患者中67%未接受俯卧位或神经肌肉阻滞。
  • 接受辅助治疗者更可能被识别ARDS、更年轻、病情更重、有肺炎、更难通气、位于欧洲高收入国家。

临床怎么用

  • 临床应提高对中重度ARDS辅助治疗的规范使用,尤其俯卧位和神经肌肉阻滞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjunctive strategies are an important part of the management of ARDS. However, their application in clinical practice remains inconsistent. RESEARCH QUESTION: We wished to determine the frequency and patterns of use of adjunctive strategies in patients with moderate to severe ARDS (Pao2/Fio2 [P/F ratio] < 150) enrolled into the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. STUDY DESIGN AND METHODS: The LUNG SAFE study was an international, multicenter, prospective cohort study of patients with severe respiratory failure, conducted in 2014 in 459 ICUs from 50 countries. The primary objective of this substudy was to determine the frequency of use of widely available (neuromuscular blockade, prone position) adjuncts vs adjuncts requiring specialized equipment (extracorporeal membrane oxygenation, inhaled vasodilators, high-frequency ventilation) in patients in the first 48 h of moderate to severe ARDS (P/F ratio < 150). RESULTS: Of 1,146 patients on invasive ventilation with moderate to severe ARDS, 811 patients (71%) received no adjunct within 48 h of ARDS onset. Of 335 (29%) that received adjunctive strategies, 252 (75%) received a single strategy, and 83 (25%) receiving more than one adjunct. Of ARDS nonsurvivors, 67% did not receive any adjunctive strategy in the first 48 h. Most patients (67%) receiving specialized adjuncts did not receive prone positioning or neuromuscular blockade. Patients that received adjuncts were more likely to have their ARDS recognized, be younger and sicker, have pneumonia, be more difficult to ventilate, and be in a European high-income country than those that did not receive adjuncts. INTERPRETATION: Three in 10 patients with moderate to severe ARDS, and only one-third of nonsurvivors, received adjunctive strategies over the first 48 h of ARDS. A more consistent and evidence-driven approach to adjunct use may reduce costs and improve outcomes in patients with moderate to severe ARDS. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02010073; URL: www.clinicaltrials.gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Duggal A, Rezoagli E, Pham T, et al. Patterns of Use of Adjunctive Therapies in Patients With Early Moderate to Severe ARDS: Insights From the LUNG SAFE Study. Chest. 2020. PMID: 32088180. doi:10.1016/j.chest.2020.01.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。